Novel Truncated Peptide Derived From circCDYL Exacerbates Cardiac Hypertrophy
- 9 May 2025
- journal article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 136 (10)
Abstract
BACKGROUND: Circular RNAs (circRNAs) have been gradually revealed to regulate the progression of heart disease in depth, showing their clinical significance. However, a mass of cardiac circRNAs still has not been functionally characterized. We aimed to explore the potential candidates that are involved in pathological cardiac hypertrophy. METHODS: Public substantial RNA-sequencing data of cardiac circRNAs were utilized to search the cardiac hypertrophy–related circRNAs. Cardiomyocyte hypertrophy in vitro was induced by Ang II (angiotensin II) treatment. Mice were subjected to Ang II infusion to induce cardiac hypertrophy in vivo. Gain-of-function and loss-of-function assays were conducted to detect the effect of RNAs or proteins in cardiac hypertrophy. RESULTS: A circRNA derived from the cdyl (chromodomain Y-like) gene was screened out and named circCDYL. Our results showed that the expression of circCDYL in primary rat cardiomyocytes was significantly induced by Ang II. Gain-of-function and loss-of-function assays demonstrated that circCDYL effectively promoted cardiomyocyte hypertrophy in vitro. CircCDYL could encode a ≈100-aa truncated CDYL peptide (tCDYL-100), whose sequence highly overlaps that of full-length CDYL. The translation of tCDYL-100 was activated by N6-methylation of circCDYL under prohypertrophic stimulation. tCDYL-100 fulfilled the prohypertrophic function of circCDYL. Mechanistically, tCDYL-100 competed with CDYL for binding REST (RE1-silencing transcription factor) and further disrupted the formation of REST-CDYL-EHMT2 (euchromatic histone-lysine N-methyltransferase 2) transcriptional repression complex, resulting in transcriptional activation of rhoa and nppb . Silence of circCDYL in mouse hearts could inhibit Ang II–induced cardiac hypertrophy, while forced expression of tCDYL-100 could cause cardiac hypertrophy. CONCLUSIONS: In summary, our study uncovered an important circRNA-derived peptide and a regulatory mechanism on transcription mediated by N6-methyladenosine-circRNA-histone methylation in pathological cardiac hypertrophy.Keywords
This publication has 84 references indexed in Scilit:
- A novel peptide encoded by circ‐SLC9A6 promotes lipid dyshomeostasis through the regulation of H4K16ac‐mediated CD36 transcription in NAFLDClinical and Translational Medicine, 2024
- N6‐methyladenosine‐modified circSTX6 promotes hepatocellular carcinoma progression by regulating the HNRNPD/ATF3 axis and encoding a 144 amino acid polypeptideClinical and Translational Medicine, 2023
- Hypoxia-induced circ-CDYL-EEF1A2 transcriptional complex drives lung metastasis of cancer stem cells from hepatocellular carcinomaCancer Letters, 2023
- Vimentin binds to a novel tumor suppressor protein, GSPT1-238aa, encoded by circGSPT1 with a selective encoding priority to halt autophagy in gastric carcinomaCancer Letters, 2022
- A novel tumour suppressor protein encoded by circMAPK14 inhibits progression and metastasis of colorectal cancer by competitively binding to MKK6Clinical and Translational Medicine, 2021
- HNRNPL Circularizes ARHGAP35 to Produce an Oncogenic ProteinAdvanced Science, 2021
- Changes in m6A RNA Methylation Contribute to Heart Failure Progression by Modulating TranslationEuropean Journal of Heart Failure, 2019
- The Translational Landscape of the Human HeartCell, 2019
- A Noncoding Regulatory RNAs Network Driven by Circ‐CDYL Acts Specifically in the Early Stages Hepatocellular CarcinomaHepatology, 2019
- Prediction of protein subcellular localizationProteins: Structure, Function, and Bioinformatics, 2006